Federal Register
Notice: FDA is making available summaries of medical and clinical pharmacology reviews of pediatric studies submitted in supplements for Wyeth’s Altace (ramipril), Lilly’s Gemzar (gemcitabine), Novartis’ Lescol (fluvastatin) and Sandostatin LAR (octreotide), and GlaxoSmithKline’s Serevent (salmeterol). These summaries are being made available consistent with the Best Pharmaceuticals for Children Act. To view this notice, click here.